Skip to main content

Recombinant Human LRRTM1 Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 4897-LR

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
4897-LR-050

Key Product Details

Source

NS0

Accession #

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Mouse myeloma cell line, NS0-derived human LRRTM1 protein
Ala35-Ile425, with a C-terminal 6-His tag

Purity

>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.01 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ala35

Predicted Molecular Mass

44.4 kDa

SDS-PAGE

70-85 kDa, reducing conditions

Activity

Measured by its ability to enhance neurite outgrowth of E16-E18 rat embryonic cortical neurons.
Able to significantly enhance neurite outgrowth when immobilized at 6-25 µg/mL on a nitrocellulose-coated microplate

Formulation, Preparation and Storage

4897-LR
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution
Reconstitute at 100 μg/mL in sterile PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: LRRTM1

Human LRRTM1 (leucine-rich repeat transmembrane neuronal 1) is a 58 - 59 kDa (predicted) type I transmembrane protein, that belongs to the LRRTM family of proteins within the leucine-rich repeat (LRR) superfamily (1). It is synthesized as a precursor with a 34 amino acid (aa) signal sequence, a 393 aa luminal region, a 21 aa transmembrane region, and a 74 aa cytoplasmic region. The luminal portion of LRRTM1 contains three N-linked glycosylation sites and 10 LRRs flanked by cysteine-rich domains (1). The cytoplasmic region contains several tyrosine, serine, and threonine residues that have potential to be phosphorylated and thus to be involved in signal transduction (1). The C-terminal also contains a conserved glutamic acid-cysteine-glutamic acid-valine sequence for potential interaction with PDZ proteins (1 - 2). Mature human LRRTM1 is 97% aa identical to mouse LRRTM1. LRRTM1 is localized to the endoplasmic reticulum (3). In the mouse, beginning at 9dpc, low levels of LRRTM1 can be detected in the overlying ectoderm of the limb bud, dorsal otic vesicle, forebrain, midbrain, hindbrain, and in neural progenitors in the central neural tube (2). In the adult brain, it is highly expressed in the brain and salivary gland, and is detected at intermediate levels in the cerebellum, spinal chord, stomach, testis, and uterus (1). Functionally, LRRTM1 may be involved in the formation of the CNS and maintenance of CNS structure and function in the adult brain (1). In addition, LRRTM1 has been shown to be a maternally suppressed gene that is associated paternally with handedness and schizophrenia (3).

References

  1. Lauren, J. et al. (2003) Genomics 81:411.
  2. Haines, B.P. and P.W.J. Rigby (2007) Gene Expr. Patterns 7:23.
  3. Francks, C. et al. (2007) Mol. Psychiatry 12:1129.

Long Name

Leucine Rich Repeat Transmembrane Neuronal 1

Alternate Names

FLJ32082, leucine rich repeat transmembrane neuronal 1, leucine-rich repeat transmembrane neuronal 1 protein, leucine-rich repeat transmembrane neuronal protein 1

Entrez Gene IDs

347730 (Human); 74342 (Mouse); 679668 (Rat)

Gene Symbol

LRRTM1

UniProt

Additional LRRTM1 Products

Product Documents for Recombinant Human LRRTM1 Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human LRRTM1 Protein, CF

For research use only

Loading...
Loading...
Loading...